Zum Inhalt springen

Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

Korro Announces $70 Million Private Placement

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement (PIPE) that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses. The PIPE is expected to close on April 22, 2024, subject to the satisfaction of customary closing conditions. Korro Announces $70 Million Private Placement

Neue KI erhöht das Niveau von Deepfakes gefährlich

Microsoft hat eine neue Studie veröffentlicht, die das präsentiert VASA, ein Framework zum Erstellen realistischer sprechender Gesichter. Die Forscher stellten ihr Modell mit dem Namen vor VASA-1mit dem realistische Videos erstellt werden können, die nur auf einem Standbild und einem Sprachclip basieren. Die Ergebnisse sind beeindruckend und übertreffen alle bisherigen Tools, die generative künstliche Intelligenz […] Die neue KI von Microsoft erhöht das Niveau von Deepfakes gefährlich [Videos]

Phase 1/1b Clinical Trial in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Neue Behandlungsstrategie für aggressive Leukämie

  • Krebs

Wissenschaftler haben eine potenzielle Behandlungsstrategie für eine aggressive Leukämieart gefunden, die auf Enzyme abzielt, die von den Zellen zur Erkennung und Anpassung an den Sauerstoffgehalt verwendet werden. Die in Nature Cancer veröffentlichten Ergebnisse zeigen, dass die Blockierung dieser sauerstoffempfindlichen Enzyme die AML in Mäusen und Patientenproben deutlich aufhalten kann, ohne die normale Produktion von Blutzellen zu beeinträchtigen. Überführung in klinische Versuche Die Enzyme können bereits mit bestehenden Medikamenten zur Behandlung von Anämie sicher blockiert werden, so dass die Forscher hoffen, dass ihre Erkenntnisse in klinische Versuche zur Behandlung von Leukämie einfließen werden. Spannenderweise hat das Team auch ein neues Medikament entwickelt, das als erstes seiner Klasse die Enzyme selektiver blockiert als die bisherigen Medikamente und so die Nebenwirkungen verringern könnte. Was ist AML? AML ist eine aggressive Form von Blutkrebs, die in der Regel ältere Erwachsene betrifft, aber auch bei… 

more »Neue Behandlungsstrategie für aggressive Leukämie

Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza

Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows, chickens and one person in Texas. This is only the second human case of H5N1 bird flu to be reported in the United States, which officials said was contracted through contact with dairy cows. The influenza subtype primarily infects wild birds and poultry, but has also spilled over into a variety of mammals. This is the first time the avian influenza A(H5N1) virus has been detected in cattle. „Thankfully, the risk of the current H5N1 case becoming widespread among people remains low,“ said Larry Schlesinger, M.D., Texas Biomed President and CEO. „But viruses adapt and evolve – especially influenza viruses – which is why it is so critical to be studying them and… 

more »Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza

EWBG: Substantial advances in Down Syndrome research

This groundbreaking study, conducted by pioneers in bioregenerative medicine and education, uses modern MRI methods to demonstrate a link between cognitive ability and brain volume changes in people with Down Syndrome. These findings suggest that early intervention techniques enhance the quality of life for individuals afflicted. EWBG, known for its groundbreaking work in stem cell therapy, has been at the forefront of this study, working closely with Heidelberg University. This collaboration demonstrates a shared commitment to transforming the care and treatment of Down Syndrome and associated diseases via cutting-edge scientific breakthroughs.

GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251

GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics, today announced that it has entered into a clinical collaboration and supply agreement with Merck (known as MSD outside the US and Canada). Under the terms of the agreement, GV20 will evaluate its lead investigational program GV20-0251, a first-in-class antibody targeting the novel immune checkpoint IGSF8, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab), in patients with advanced solid tumors in an ongoing Phase I study. https://classic.clinicaltrials.gov/ct2/show/NCT05669430

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regimen achieved sustained remission compared to 29 percent of patients receiving placebo in combination with a 52-week steroid taper regimen (p=0.0019).

Bosch und R-Biopharm stärken Analyseplattform Vivalytic / Einsatz von innovativer Bosch BioMEMS-Technologie für PCR-Tests auf multiresistente Bakterien geplant

Waiblingen (ots) – Bosch und R-Biopharm investieren zusammen 150 Millionen Euro in die Entwicklung neuer PCR-Tests und in den Vertrieb. Neuartige BioMEMS-Technologie soll bei der Entwicklung eines PCR-Tests für multiresistente gramnegative Bakterien (MRGN) eingesetzt werden. BioMEMS-Chip ermöglicht das zeitgleiche Testen auf bis zu 250 genetische Merkmale in teils weniger als 15 Minuten. Innovativ, dynamisch und […] Weitere Medizintechnik-Partnerschaft: Bosch und R-Biopharm stärken Analyseplattform Vivalytic / Einsatz von innovativer Bosch BioMEMS-Technologie für PCR-Tests auf multiresistente Bakterien geplant